Compare · ALMS vs NVO
ALMS vs NVO
Side-by-side comparison of Alumis Inc. (ALMS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 61.0x ALMS ($3.65B).
- ALMS has been more active in the news (8 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for ALMS).
- Company
- Alumis Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $3.65B
- $222.81B
- 1M return
- -
- +15.47%
- 1Y return
- -
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 8
- 5
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ALMS
- Chief Legal Officer Pangali Sanam sold $140,000 worth of shares (5,000 units at $28.00) and exercised 5,000 shares at a strike of $5.06 (SEC Form 4)
- Director Tetrault Lynn A. was granted 3,553 shares (SEC Form 4)
- Director Yao Zhengbin was granted 3,553 shares, increasing direct ownership by 15% to 27,082 units (SEC Form 4)
- Director Srivastava Sapna was granted 3,553 shares (SEC Form 4)
- Director Machado Patrick was granted 3,553 shares (SEC Form 4)
- Director Akkaraju Srinivas was granted 3,553 shares (SEC Form 4)
- Alumis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Alumis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Chief Medical Officer Drappa Jorn exercised 26,852 shares at a strike of $6.65, increasing direct ownership by 83% to 59,339 units (SEC Form 4)
- SEC Form DEFA14A filed by Alumis Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S